GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
NCT ID: NCT04601584
Last Updated: 2024-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
36 participants
INTERVENTIONAL
2020-10-15
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
NCT01035216
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
NCT04872478
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
NCT01690624
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
NCT02345382
Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia
NCT01573247
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
More than 7,200 new cases of ALL are diagnosed annually in the European Union (EU), with approximately 40% (approximately 3,000 cases) occurring in adults The main reason for the failure of treatment of acute B-cell lymphoblastic leukemias (B-ALL) is the primary refractoriness to chemical exposure and relapses of the disease, which actually occur in 40-50% of adult patients with ALL. The prognosis in these cases is regarded as extremely unfavorable. Escalation of the chemotherapeutic approach is associated with the development of severe toxic infectious and hemorrhagic complications.
The active substance of the preparation GNR-084 is a bispecific antibody to CD19 / CD3 in the BiMS format (bispecific IgG-like molecules).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GNR-084, dose level 1
Anti-CD19/CD3 antibody
Cohort 1, GNR-084
0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
GNR-084, dose level 2
Anti-CD19/CD3 antibody
Cohort 2, GNR-084
0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
GNR-084, dose level 3
Anti-CD19/CD3 antibody
Cohort 3, GNR-084
1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
GNR-084, dose level 4
Anti-CD19/CD3 antibody
Cohort 4, GNR-084
4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
GNR-084, dose level 5
Anti-CD19/CD3 antibody
Cohort 5, GNR-084
10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
GNR-084, dose level 6
Anti-CD19/CD3 antibody
Cohort 6, GNR-084
20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cohort 1, GNR-084
0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Cohort 2, GNR-084
0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Cohort 3, GNR-084
1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Cohort 4, GNR-084
4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Cohort 5, GNR-084
10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Cohort 6, GNR-084
20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Men and women between aged 18 to 45 inclusive;
3. Patients with incurable morphologically / immunophenotypically confirmed refractory/ relapse of B-cell precursors CD19-positive acute lymphoblastic leukemia from (Ph "-" or Ph "+").
4. Two or more previous lines of anti-leucosis therapy.
5. 5-50% of bone marrow blast cells at screening;
6. Functional status on the scale of the Eastern Cooperative Oncology Group (ECOG) 0-2 points at the screening;
7. Life expectancy ≥ 60 days;
Exclusion Criteria
2. Active and widespread chronic graft versus host (GVHD) reaction (grade II-IV), including taking immunosuppressants for the prevention and treatment of GVHD within 2 weeks prior the GNR-084 infusion;
3. Investigator and / or sponsor has doubts that patient will complete the study due to rapid disease progression;
4. Chemotherapeutic agent using within 14 days prior the first GNR-084 infusion;
Exceptions:
* Emergency leukapheresis;
* Emergency hydroxyurea using due to hyperleukocytosis for ≤ 7 days;
* Other supportive care, including antibiotics, at Investigator's discretion
5. Biochemical blood test:
* The level of total bilirubin\> 1.5 upper limit of norm;
* Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)\> 3 upper limit of norm;
* Glomerular filtration rate (GFR) level ≤30 (СKD-EPI)
6. Medical history of blinatumomab and other bispecific antibodies using;
7. Persistent toxicity event of 3rd and 4th severity degrees (CTCAE ver 5.0) due to previous treatment;
8. HIV-positive status and / or detection of any hepatitis B and / or hepatitis C blood markers;
9. Severe cardiovascular diseases: uncontrolled arterial hypertension, New York Heart Association (NYHA) functional class III or IV chronic heart failure, unstable angina pectoris, stroke, myocardial infarction, transient ischemic attack, coronary artery bypass grafting and coronary revascularization within last 12 months, or signs of pericardial effusion;
10. Individual sensitivity to:
* GNR-084 components / excipients;
* human or humanized investigational drug antibodies;
11. Major surgical interventions, accompanied by hospitalization and anesthesia application within 30 days before the patient is included in the study (biopsy is not a significant surgical intervention);
12. Any other malignant neoplasm presence at the present time or within 5 years prior to inclusion in the study;
13. Known suspected Central Nervous System (CNS) lesion by any genesis now or in medical history, including, but not limited to: neuroleukemia, epilepsy, ischemic or hemorrhagic stroke, severe traumatic brain injury, dementia, Parkinson's disease, organic brain damage, cerebellar disorders, psychosis;
14. Extramedullary lesion of any localization;
15. Other clinical trials participation within 30 days before screening;
16. Mental, physical and other reasons hindering patient to adequately assess their behavior and correctly comply with the conditions of the research protocol;
17. Pregnancy and / or lactation;
18. Male and female patients refusal to use adequate methods of contraception throughout the study;
19. Drug addiction;
20. Alcohol addiction.
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AO GENERIUM
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oksana A. Markova, MD
Role: STUDY_CHAIR
AO GENERIUM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia)
Moscow, , Russia
Almazov National Medical Research Centre
Saint Petersburg, , Russia
Pavlov First Saint Petersburg State Medical University
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical trial registry, Ministry of Health of Russian Federation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#652 eff date 12.11.2019
Identifier Type: OTHER
Identifier Source: secondary_id
BIM-HEM-I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.